Affinity Chromatography Compounds for Human Serum Albumin Purification
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
There is a need for improved compounds that can effectively purify human serum albumin and its fusion proteins from biomolecules and extend the half-life of therapeutic peptides and small molecules by binding specifically to human serum albumin, as existing methods lack sufficient selectivity and efficacy.
Innovation Solution
Development of novel compounds with specific affinity to human serum albumin, which can be conjugated to therapeutic agents and immobilized on agarose or other substrates for affinity chromatography, providing enhanced selectivity and prolonged release of therapeutic agents by binding to human serum albumin.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Measurement precision
If existing affinity chromatography ligands are used to purify human serum albumin, then purification can be performed, but the selectivity is insufficient and cannot effectively separate HSA from other biomolecules
Solution Approach 1:
The patent modifies the chemical structure of affinity ligands by introducing specific functional groups and molecular configurations that enhance binding affinity and selectivity for human serum albumin. The compounds feature optimized hydrophobic regions, hydrogen bonding capabilities, and spatial arrangement that specifically recognize HSA binding sites, thereby improving selectivity while maintaining effective purification capacity.
Solution Approach 2:
The invention employs composite affinity ligands that combine multiple functional moieties within a single molecule. These composite structures include hydrophobic domains, polar groups, and specific geometric arrangements that work synergistically to achieve high selectivity for HSA, effectively distinguishing it from other serum proteins through multi-point binding interactions.
2Duration of action of moving object
If therapeutic agents are administered without half-life extension, then immediate therapeutic effect is achieved, but the duration of action is too short requiring frequent dosing
Solution Approach 1:
The patent introduces human serum albumin as an intermediary carrier molecule that binds to therapeutic agents through the developed affinity ligands. This HSA-therapeutic complex circulates in the bloodstream with extended half-life, as albumin is naturally retained by the kidneys. The intermediary HSA molecule effectively prolongs the residence time of the therapeutic agent without requiring modification of the active drug molecule itself.
Solution Approach 2:
The invention creates a nested structure where the therapeutic agent is bound within the HSA-ligand complex. The therapeutic molecule is effectively 'nested' within the protein complex, protected from rapid clearance mechanisms while maintaining its biological activity. This nested configuration allows the small therapeutic molecule to benefit from the long circulation half-life of the large HSA carrier.
3Device complexity
If small molecules are used for affinity chromatography, then the process is simple, but the selectivity and binding affinity are insufficient
Solution Approach 1:
The patent transforms simple small molecule ligands into optimized affinity compounds by modifying key molecular parameters including size, shape, hydrophobicity, and functional group distribution. These parameter optimizations enable the ligands to achieve high binding affinity and selectivity for HSA while maintaining the practical advantages of small molecule chemistry, such as ease of synthesis and immobilization on chromatography supports.
Applied Scientific Principles
This section explains which scientific principles are used to turn an abstract innovation direction into a practical engineering solution.
Function Achieved in This Case
The compounds demonstrate significantly greater selectivity in purifying human serum albumin and its fusion proteins, and when conjugated to therapeutic agents, they extend the half-life of these agents in the bloodstream, offering improved purification and prolonged therapeutic effects.
Implementation Method 1
small molecules which bind to human serum albumin have been described for use in purifying biomolecules such as serum albumins including human serum albumin (HSA)
Data Source
Figure 1
Figure 2
Figure 3
AI summary
Compounds useful for affinity chromatography as presented, more particularly for use in affinity chromatography to purify serum albumin, especially human serum albumin (HSA) and fusion proteins thereof. Methods for extending the half-life of therapeutic agents are also presented, particularly therapeutic peptide agents and small molecules, such as by conjugation of compounds described herein to the therapeutic peptide or small molecule, which, upon administration, binds to HSA, thereby providing a prolonged release of the therapeutic agent.